Unicycive Therapeutics, Inc. (UNCY) Stock Price & Analysis
Unicycive Therapeutics, Inc. (UNCY) rose 9.16% to USD 7.27 as of June 10, 2026 at 09:20 UTC, according to Nexqual real-time market data.
UNCY last closed at USD 6.66; the session ranged USD 6.77–7.31 on volume of 867,605 shares. Market capitalization is $199.15M, with a 52-week range of USD 3.71–8.74 (NCM). Source: Nexqual, June 10, 2026 at 09:20 UTC.
Key Statistics (as of June 10, 2026 at 09:20 UTC)
| Price | USD 7.27 |
|---|---|
| Change | ▲ 9.16% (up) |
| Previous Close | USD 6.66 |
| Open | USD 6.77 |
| Day Range | USD 6.77 – 7.31 |
| 52-Week Range | USD 3.71 – 8.74 |
| Volume | 867,605 shares |
| Market Cap | $199.15M |
| Exchange | NCM |
Technical Analysis (UNCY)
Nexqual's technical model rates UNCY "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.87 (neutral) |
| vs SMA50 | Below (USD 7.34) |
| MACD | -0.15 (negative) |
Analyst Ratings (UNCY)
Wall Street analysts rate UNCY "Strong Buy" based on 10 analysts, with a mean price target of USD 41.3 (range USD 18–90), per Nexqual as of June 10, 2026 at 09:20 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 41.3 |
| High Target | USD 90 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (UNCY)
| EPS Estimate | USD -0.43 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.82 vs est -0.46 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.53 ▲ beat |
| 2025-06-30 | USD -0.52 vs est -0.7 ▲ beat |
Source: Nexqual, June 10, 2026 at 09:20 UTC.
Financials & Fundamentals (UNCY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -163.14% |
| Debt / Equity | 2.16 |
| Current Ratio | 2.4 |
| Total Cash | $54.59M |
| Total Debt | $815,000 |
| Free Cash Flow | $-7.11M |
Source: Nexqual, June 10, 2026 at 09:20 UTC.
Financial Health Score (UNCY)
Nexqual rates Unicycive Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $55M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$29M |
| Efficiency | Critical — ROE -163%, ROA -40.6% |
Ownership (UNCY)
| Insider Ownership | +2.36% |
|---|---|
| Institutional Ownership | +37.65% |
| Shares Outstanding | 27.39M |
| Float | 24.28M |
| Short % of Float | +10.88% |
Source: Nexqual, June 10, 2026 at 09:20 UTC.
Leadership (UNCY)
Unicycive Therapeutics, Inc. is led by Shalabh K. Gupta M.D., MPA (age 51), Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 09:20 UTC.
| Founder, Chairman, CEO & President | Shalabh K. Gupta M.D., MPA (age 51) |
|---|---|
| Executive Vice President of Pharmaceutical and Business Operations | Pramod Gupta (age 65) |
| Executive Vice President of Corporate Strategy | Douglas Jermasek (age 64) |
| Chief Financial Officer | John W. Townsend (age 63) |
Major Backers & Investors (UNCY)
Notable institutional backers of Unicycive Therapeutics, Inc. include Vivo Capital, LLC, Millennium Management, Octagon Capital Advisors LP, according to Nexqual as of June 10, 2026 at 09:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vivo Capital, LLC | 6.53% |
| Millennium Management | 5.11% |
| Octagon Capital Advisors LP | 3.65% |
| Nantahala Capital Management, LLC | 3.43% |
| Great Point Partners LLC | 2.91% |
| Logos Global Management LP | 1.73% |
| Citadel | 0.86% |
| Integral Health Asset Management, LLC | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.92% |
| Geode Capital | 0.74% |
Source: Nexqual, June 10, 2026 at 09:20 UTC.
From Unicycive Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- In September 2024, we submitted a New Drug Application (NDA) for OLC to the FDA.
- We completed both studies and submitted the data for the FDA's review during the pre-NDA (New Drug Application) meeting request.
- Our technology for UNI-494 is licensed from Sphaera Pharmaceutical Private Limited, a Singapore-based company ("Sphaera"), with offices in India and the U.S.
Partnerships
- In select Asian markets, we have entered into a licensing agreement with Lotus Pharmaceutical Co., Ltd., which is responsible for regulatory filings, commercialization, and distribution within its designated regions.
- If and when any of our product candidates are approved, we plan to obtain manufacturing capacity through contract manufacturing organizations (CMOs) to meet projected needs for commercial sale quantities and serve patient needs.   With regards to manufacturing, testing and potential commercial supply of oxylanthanum carbonate, on October 31, 2020, the Company entered into an agreement with Shilpa Medicare Ltd ("Shilpa") based in India.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| RNAZ | TransCode Therapeutics, Inc. | USD 4.98 | ▼ 11.07% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.2 | ▲ 1.69% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:20 UTC. This page is informational and not investment advice.